Fig. 1 · Structure

Documents & Downloads

SM-164

Cat. No. A15800 CAS 957135-43-2

cIAP-2 antagonist

SM-164 is a potent cell-permeable and bivalent Smac mimetic which bind to a XIAP protein with a Ki value of 0.56 nM, and binds to cIAP-1 and cIAP-2 proteins with Ki values of 0.31 and 1.1 nM, respectively.

In Stock

Publications for SM-164

3 publications citing this product

  1. Antonella Antignani, .et al. , FASEB J, 2023, Dec;37(12):e23292 PMID: 37971407
  2. Hanna Yuk, .et al. , Antioxidants (Basel), 2021, Aug 25;10(9):1347 PMID: 34572979
  3. Caroline Moerke, .et al. , Cell Death Differ, 2018, Nov 15 PMID: 30442947

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

SM-164 is a bivalent Smac mimetic. It displaced a Smac-based tracer from recombinant XIAP containing BIR2 and BIR3 with an IC50 of 1.39 ± 0.17 nM (SD). In cellular experiments, SM-164 rapidly reduced cIAP-1 abundance, and MG-132 blocked this loss, supporting proteasome-dependent degradation. Binding potency and cellular degradation are distinct assay endpoints. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
cIAP-1 Ki 0.31 nM
cIAP-2 Ki 1.1 nM
cIAP  

Cellular Effect

Cell Line Activity Value Description Reference
MDA-MB-231 IC50 0.039 μM Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay [PMID: 23062821]
MDA-MB-231 IC50 3.3 nM Growth inhibition of human MDA-MB-231 cells after 2 to 3 hrs by WST8 assay [PMID: 21462933]
MDA-MB-231 IC50 6.8 nM Growth inhibition of human MDA-MB-231 cells after 4 days by WST8 assay [PMID: 22148838]
SK-OV-3 IC50 16 nM Growth inhibition of human SKOV3 cells after 4 days by WST8 assay [PMID: 22148838]

SM-164 Research Summary

This section summarizes 3 in vitro studies and 2 in vivo studies of SM-164 from 4 published references.

SM-164 In Vitro Studies

In HT-29 and U937 cells, SM-164 was used with TNFα and the caspase inhibitor zVAD to trigger cell death. Phenhydan suppressed death and associated necroptosis-pathway phosphorylation in this combination model. These findings describe a conditional combination response and do not establish SM-164-alone cytotoxicity. [3]

Competitive binding to XIAP containing BIR2 and BIR3

Biochemical assay · Recombinant human XIAP residues 120–356; competitive displacement of Smac-1F tracer. [1]

Compound 4 (SM-164) displaced the tracer with IC50 1.39 ± 0.17 nM (SD). The stereoisomer 6 was weaker (71.5 ± 34.9 nM), and inactive control 5 had IC50 >100,000 nM. This is a binding-assay endpoint, not a cellular treatment dose or Ki.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Displacement of Smac-1F from XIAP L-BIR2-BIR3IC50 1.39 ± 0.17 nM (SD; n not specified in selected material)[1]

Literature-Reported Treatment Conditions

Treatment concentration
Compound concentration series; XIAP 3 nM and Smac-1F 0.5 nM.
Exposure duration
2 h before polarization measurement.
Method
Competitive fluorescence polarization; nonlinear least-squares IC50 fitting. XIAP plus tracer and tracer alone define 0% and 100% displacement; AVPI peptide is an assay control.
Reported limits
Replicate number for Figure 8 and compound vehicle are not specified in the selected assay description. Final counterion after purification is not established.
Methods and source locations

Compound reported in the paper: SM-164; Compound label in the paper: compound 4 (SM-164)

Applies to the SM-164 material reported in this paper. Catalog SMILES lacks stereochemical specification; final form and Adooq lot equivalence are not established. No salt or dose conversion is made.

Figure 6 compound 4; Figure 8 image/caption and quantitative-binding Results; Experimental compound 4 and XIAP L-BIR2-BIR3 FP assay

Displacement of Smac-1F from XIAP L-BIR2-BIR3: Fluorescence polarization, 2 h incubation; fitted IC50. — Figure 8 image legend; quantitative-binding Results; Experimental FP assay

Cellular cIAP-1 degradation and proteasome-inhibitor control

Cell-based study · Human MDA-MB-231 breast cancer cells; HCT116 colon cancer cells in the MG-132 control comparison. [2]

In MDA-MB-231 cells, SM-164 reduced cIAP-1 after 60 min, with a marked decrease at 1 nmol/L and undetectable levels at 10–100 nmol/L as described by the authors. MG-132 blocked the rapid cIAP-1 loss in both MDA-MB-231 and HCT116 cells. Degradation in HCT116 should not be interpreted as proof of single-agent cell killing.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cellular cIAP-1 abundance and proteasome dependencequalitative immunoblot Marked reduction at 1 nmol/L after 60 min; undetectable cIAP-1 at 10–100 nmol/L; MG-132 blocked rapid loss.[2]

Literature-Reported Treatment Conditions

Treatment concentration
SM-164 0.1, 1, 10 and 100 nmol/L in Figure 3C; 100 nmol/L in Figure 3D,E.
Exposure duration
60 min dose series; 100 nmol/L time course from 5 min to 24 h; MG-132 comparison at 10 min.
Method
Western blotting for cIAP-1, XIAP and β-actin; untreated and less-active SM-123/SM-173 controls; comparison with SM-122; MG-132 cotreatment control.
Co-treatment
MG-132 proteasome-inhibitor control in Figure 3E; SM-164-alone dose/time series in Figure 3C,D.
Reported limits
MG-132 dose and pretreatment duration were not established from the main-text/figure material read. Compound vehicle and final salt are not specified there; SI PDF was not retrieved.
Methods and source locations

Compound reported in the paper: SM-164; Compound label in the paper: SM-164

Applies to the SM-164 material reported in this paper. Catalog SMILES lacks stereochemical specification; final form and Adooq lot equivalence are not established. No salt or dose conversion is made.

Figure 3C-E images/caption; Results “Both SM-164 and SM-122 induce rapid cIAP-1 degradation in cancer cells”; Methods Drugs, Cell lines, Western blot analysis

Cellular cIAP-1 abundance and proteasome dependence: Western blot; β-actin loading control; untreated, analog and inhibitor controls. No densitometric IC50 derived. — Figure 3C-E; corresponding cIAP-1 degradation Results

Phenhydan suppresses death in an SM-164-containing combination

Cell-based study · Human HT-29 and U937 cells; matched FACS and Western-blot samples in Figure 2C,D. [3]

The TNFα/SM-164/zVAD combination caused time-dependent cell death in both human cell models. Phenhydan pretreatment suppressed this response and the associated necroptosis-pathway phosphorylation. The study tests combination-induced death and its inhibition; it does not quantify SM-164-alone efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Death induced by TSZ and inhibited by Phenhydanqualitative time-course comparison Phenhydan suppressed TSZ-induced death; mean ± SEM, n = 4 independent repeats.[3]
Necroptosis-pathway activation in the matched cell samplesqualitative immunoblot Phenhydan reduced pathway phosphorylation; one representative blot of four independent experiments.[3]

Literature-Reported Treatment Conditions

Treatment concentration
SM164 1 µM; TNFα 100 ng/ml; zVAD 25 µM; Phenhydan 1 mM where indicated.
Exposure duration
Up to 8 h stimulation at 37 °C; Phenhydan added 30 min beforehand.
Method
Annexin V/7-amino-actinomycin D flow cytometry; paired immunoblots for RIPK1, RIPK3, MLKL and phosphorylated proteins; β-actin loading control.
Vehicle
Vehicle comparator indicated in figure; composition not specified in selected material.
Co-treatment
TNFα + SM164 + zVAD (TSZ), with or without Phenhydan.
Reported limits
No SM164-alone arm in the selected design. Counterion, catalog number and lot were not reported in the selected reagent description.
Methods and source locations

Compound reported in the paper: SM-164; Compound label in the paper: SM-164

Applies to the SM-164 material reported in this paper. Catalog SMILES lacks stereochemical specification; final form and Adooq lot equivalence are not established. No salt or dose conversion is made.

Figure 2C,D image and full caption; Results initial Phenhydan section; Methods Cell lines, Reagents and antibodies, Assessment of cell death in vitro, Analysis of cell death by western blotting

Death induced by TSZ and inhibited by Phenhydan: Annexin V/7-AAD FACS. No exact percentages inferred from bars. — Figure 2C,D image/caption

Necroptosis-pathway activation in the matched cell samples: Western blot on split samples also used for FACS; total-protein and β-actin controls. — Figure 2C,D image/caption

SM-164 In Vivo Studies

SM-164 produced partial regression of MDA-MB-231 xenografts at 5 mg/kg i.v. under a two-week schedule. In a separate 2LMP xenograft study, SM-164 alone at 5 mg/kg lacked significant antitumor activity, whereas SM-164 plus TRAIL caused regression. The differing results remain specific to their models and treatment conditions; their cause is unresolved. [2,4]

Single-agent efficacy in MDA-MB-231 xenografts

Animal study · SCID mice bearing established MDA-MB-231 xenografts; 8–10 mice per group. [2]

SM-164 inhibited tumor growth at 1 mg/kg and produced partial regression at 5 mg/kg under the reported schedule. Values are mean tumor volumes ± SE. This longitudinal efficacy experiment is distinct from the paper’s single-dose pharmacodynamic cohorts.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volume at 5 mg/kgmean tumor volume ± SE 147 ± 54 mm³ (day 25) to 54 ± 32 mm³ (day 36); 65% reduction reported; 8–10 mice/group.[2]

Conditions shared by the study groups

Route
Intravenous
Frequency
Daily, 5 days/week
Treatment course
2 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle controlReference control armTumors grew during follow-up.[2]
SM-164 1 mg/kgVehicle-treated tumor-bearing miceAuthors report complete inhibition of tumor growth during treatment.[2]
SM-164 5 mg/kgVehicle-treated tumor-bearing miceMean tumor volume decreased from 147 ± 54 mm³ on day 25 to 54 ± 32 mm³ on day 36; 65% reduction reported.[2]
Taxotere comparator
7.5 mg/kg
Vehicle-treated tumor-bearing miceInhibited tumor growth but did not induce regression in this experiment.[2]
Vehicle control
Model: SCID mice bearing MDA-MB-231 xenografts
Reported limits: Vehicle composition and sex/age are not established in the acquired efficacy description.
SM-164 1 mg/kg
Model: SCID mice bearing MDA-MB-231 xenografts
Reported limits: Vehicle composition and sex/age are not established in the acquired efficacy description.
SM-164 5 mg/kg
Model: SCID mice bearing MDA-MB-231 xenografts
Reported limits: Vehicle composition and sex/age are not established in the acquired efficacy description.
Taxotere comparator
Model: SCID mice bearing MDA-MB-231 xenografts
Reported limits: Vehicle composition and sex/age are not established in the acquired efficacy description.
Methods and source locations

Compound reported in the paper: SM-164; Compound label in the paper: SM-164

Applies to the SM-164 material reported in this paper. Catalog SMILES lacks stereochemical specification; final form and Adooq lot equivalence are not established. No salt or dose conversion is made.

Figure 6E image/caption; In vivo antitumor efficacy study methods; final paragraph of in vivo Results

Tumor volume at 5 mg/kg: Repeated tumor measurements; exact values taken from Results text, not estimated from graph. — Figure 6E image/caption; In vivo antitumor efficacy study methods; final paragraph of in vivo Results

Vehicle control · Figure 6E image/caption; In vivo antitumor efficacy study methods; final paragraph of in vivo Results

SM-164 1 mg/kg · Figure 6E image/caption; In vivo antitumor efficacy study methods; final paragraph of in vivo Results

SM-164 5 mg/kg · Figure 6E image/caption; In vivo antitumor efficacy study methods; final paragraph of in vivo Results

Taxotere comparator · Figure 6E image/caption; In vivo antitumor efficacy study methods; final paragraph of in vivo Results

Combination efficacy with TRAIL and inactive monotherapy arms

Animal study · Nude athymic mice bearing established 2LMP breast cancer xenografts; 8–12 mice/group in methods/caption. [4]

SM-164 plus TRAIL caused regression, whereas each single-agent arm lacked significant antitumor activity in this 2LMP model. Tumor volumes and body weights were plotted as mean ± SEM. This response differs from the 2008 parental MDA-MB-231 experiment; the selected sources do not establish the reason.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor-volume response to SM-164/TRAILreported change in mean tumor volume 80% reduction by treatment end in the combination group; neither monotherapy had significant antitumor activity.[4]

Conditions shared by the study groups

Frequency
Daily, 5 days/week
Treatment course
2 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle controlReference control armTumors continued to grow.[4]
SM-164 alone
5 mg/kg
Vehicle-treated tumor-bearing miceNo significant antitumor activity reported; mean tumor volume exceeded 1000 mm³ on day 43.[4]
TRAIL alone
10 mg/kg
Vehicle-treated tumor-bearing miceNo significant antitumor activity reported; mean tumor volume exceeded 1000 mm³ on day 43.[4]
SM-164 plus TRAIL
SM-164 5 mg/kg + TRAIL 10 mg/kg
Vehicle-treated tumor-bearing miceCombination caused regression; authors report an 80% reduction in mean tumor volume by treatment end. Slight, statistically insignificant weight loss was followed by weight recovery by day 33.[4]
Vehicle control
Model: Nude athymic mice bearing established 2LMP breast cancer xenografts; 8–12 mice/group in methods/caption.
Reported limits: Vehicle composition and sex/age are not established in the acquired efficacy description.
SM-164 alone
Model: Nude athymic mice bearing established 2LMP breast cancer xenografts; 8–12 mice/group in methods/caption.
Route: Intravenous
Reported limits: Vehicle composition and sex/age are not established in the acquired efficacy description.
TRAIL alone
Model: Nude athymic mice bearing established 2LMP breast cancer xenografts; 8–12 mice/group in methods/caption.
Route: Intraperitoneal
Reported limits: Vehicle composition and sex/age are not established in the acquired efficacy description.
SM-164 plus TRAIL
Model: Nude athymic mice bearing established 2LMP breast cancer xenografts; 8–12 mice/group in methods/caption.
Route: SM-164 intravenous; TRAIL intraperitoneal
Reported limits: Vehicle composition and sex/age are not established in the acquired efficacy description.
Methods and source locations

Compound reported in the paper: SM-164; Compound label in the paper: SM-164

Applies to the SM-164 material reported in this paper. Catalog SMILES lacks stereochemical specification; final form and Adooq lot equivalence are not established. No salt or dose conversion is made.

Figure 6D image/caption; In vivo antitumor efficacy methods; Results combination-efficacy paragraphs

Tumor-volume response to SM-164/TRAIL: Tumor-volume time course; Figure 6D displays mean ± SEM; text supplies reduction. — Figure 6D image/caption; In vivo antitumor efficacy methods; Results combination-efficacy paragraphs

Vehicle control · Figure 6D image/caption; In vivo antitumor efficacy methods; Results combination-efficacy paragraphs

SM-164 alone · Figure 6D image/caption; In vivo antitumor efficacy methods; Results combination-efficacy paragraphs

TRAIL alone · Figure 6D image/caption; In vivo antitumor efficacy methods; Results combination-efficacy paragraphs

SM-164 plus TRAIL · Figure 6D image/caption; In vivo antitumor efficacy methods; Results combination-efficacy paragraphs

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 957135-43-2
Applications cIAP-2 antagonist
Formula C62H84N14O6
Molecular Weight 1121.42
SMILES
CC(C(=O)NC1CCCCC2CCC(N2C1=O)C(=O)NC(C3=CC=CC=C3)C4=CN(N=N4)CCCCC5=CC=C(C=C5)CCCCN6C=C(N=N6)C(C7=CC=CC=C7)NC(=O)C8CCC9N8C(=O)C(CCCC9)NC(=O)C(C)NC)NC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 3 mg/mL (2.67 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

SM-164 Research References

  1. [1] Sun H, Nikolovska-Coleska Z, Lu J, et al. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. Journal of the American Chemical Society (2007). PMID: 17999504 DOI: 10.1021/ja074725f Source material
  2. [2] Lu J, Bai L, Sun H, et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer research (2008). PMID: 19010913 DOI: 10.1158/0008-5472.can-08-2655 Source material
  3. [3] Moerke C, Jaco I, Dewitz C, et al. The anticonvulsive Phenhydan® suppresses extrinsic cell death. Cell death and differentiation (2019). PMID: 30442947 DOI: 10.1038/s41418-018-0232-2 Source material
  4. [4] Lu J, McEachern D, Sun H, et al. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. Molecular cancer therapeutics (2011). PMID: 21372226 DOI: 10.1158/1535-7163.mct-10-0864 Source material

Publications

3 publications citing this product

  1. Antonella Antignani, .et al. , FASEB J, 2023, Dec;37(12):e23292 PMID: 37971407
  2. Hanna Yuk, .et al. , Antioxidants (Basel), 2021, Aug 25;10(9):1347 PMID: 34572979
  3. Caroline Moerke, .et al. , Cell Death Differ, 2018, Nov 15 PMID: 30442947

Added to your cart

View Cart Checkout
Loading...